word,tfidf
evaluate,0.40555900986900917
disease,0.2253402728681673
month,0.21763575899782636
compare,0.2133939944289686
week,0.21268949174787577
survival,0.18115590563911488
graft,0.18115590563911488
relapse,0.16790059547039918
versus,0.16348215874749392
host,0.15464528530168342
effect,0.13849548299861678
12,0.13255310168715723
response,0.13255310168715723
cells,0.128134664964252
incidence,0.10881787949891318
cell,0.10604248134972578
assess,0.10387161224896257
efficacy,0.10387161224896257
free,0.10387161224896257
overall,0.0972056079039153
days,0.09278717118101006
prophylaxis,0.08888964599868693
mammography,0.08786811535310472
immune,0.08395029773519959
estimate,0.083334043123769
life,0.07953186101229434
objective,0.07777844024885107
quality,0.0751134242893891
21,0.07222283737393313
tomosynthesis,0.0715834854771287
change,0.06924774149930839
terms,0.06924774149930839
rate,0.06627655084357861
synthetic,0.06442513692941583
tumor,0.06430147424935778
100,0.06430147424935778
mortality,0.06430147424935778
safety,0.06185811412067337
biological,0.061111631624097267
cumulative,0.061111631624097267
baseline,0.05935520699940719
group,0.05743967739776813
24,0.05743967739776813
primary,0.05743967739776813
best,0.05743967739776813
secondary,0.05743967739776813
failure,0.05743967739776813
objectives,0.056486645584138746
compared,0.05440893974945659
16,0.05440893974945659
activity,0.05302124067486289
transplantation,0.05302124067486289
inclusion,0.05302124067486289
grade,0.05302124067486289
uveitis,0.05302124067486289
remission,0.05302124067486289
acuity,0.0500004258742614
corrected,0.0500004258742614
allogeneic,0.049462672499506
adalimumab,0.049462672499506
arm,0.04860280395195765
randomization,0.04860280395195765
mesenchymal,0.0445164052495554
visual,0.0445164052495554
stromal,0.0445164052495554
graall,0.044444822999343464
regimen,0.044444822999343464
complete,0.04418436722905241
systemic,0.04418436722905241
infusion,0.04418436722905241
55,0.04418436722905241
transplant,0.04418436722905241
acute,0.04418436722905241
main,0.04418436722905241
changes,0.04393405767655236
therapy,0.03976593050614717
care,0.03976593050614717
severe,0.03976593050614717
analysis,0.03976593050614717
aiec,0.03957013799960479
sclerosis,0.03957013799960479
reconstitution,0.038889220124425534
endoscopic,0.038889220124425534
profile,0.038889220124425534
active,0.03534749378324193
level,0.03534749378324193
concentration,0.03534749378324193
stem,0.03534749378324193
post,0.03534749378324193
progression,0.03534749378324193
tocilizumab,0.034623870749654194
tolerance,0.034623870749654194
hospitalization,0.034623870749654194
worsening,0.0333336172495076
consolidation,0.03318205879890225
cryostem,0.03318205879890225
odv,0.03318205879890225
birads,0.03138146976896597
prevalence,0.03138146976896597
28,0.03138146976896597
correlation,0.03138146976896597
treated,0.030929057060336686
placebo,0.030929057060336686
chronic,0.030929057060336686
anti,0.030929057060336686
10,0.030929057060336686
early,0.030929057060336686
behcets,0.030929057060336686
stage,0.029677603499703595
index,0.029677603499703595
2014,0.029677603499703595
score,0.029677603499703595
function,0.029677603499703595
classification,0.029677603499703595
partial,0.029677603499703595
nk,0.029677603499703595
metabolism,0.02863339419085148
ultrasound,0.02863339419085148
irradiation,0.02863339419085148
anakinra,0.02863339419085148
mofetil,0.02777801437458967
thymoglobulin,0.02777801437458967
mycophenolate,0.02777801437458967
arms,0.02777801437458967
benefit,0.026510620337431446
administration,0.026510620337431446
year,0.026510620337431446
levels,0.026510620337431446
follow,0.026510620337431446
hematopoietic,0.026510620337431446
ocular,0.026510620337431446
conditioning,0.026510620337431446
count,0.026510620337431446
hhv8,0.025105175815172777
atlg,0.025105175815172777
fludrocortisone,0.025105175815172777
keytruda,0.025105175815172777
superior,0.025105175815172777
markers,0.025105175815172777
monitored,0.025105175815172777
cost,0.025105175815172777
simons,0.025105175815172777
characterize,0.025105175815172777
hydrocortisone,0.025105175815172777
plus,0.025105175815172777
truly,0.02488654409917669
inflammation,0.024731336249753
chamber,0.024731336249753
factors,0.024731336249753
infectious,0.024731336249753
composite,0.024731336249753
36,0.024731336249753
engraftment,0.024731336249753
endpoint,0.024731336249753
adult,0.024731336249753
effects,0.024731336249753
antibiotic,0.024731336249753
sct,0.024731336249753
central,0.024731336249753
obtained,0.024731336249753
term,0.024731336249753
outcomes,0.024731336249753
180,0.022222411499671732
analyses,0.022222411499671732
design,0.022222411499671732
cytokine,0.022222411499671732
search,0.022222411499671732
improvement,0.022222411499671732
500,0.022222411499671732
white,0.022222411499671732
nervous,0.022222411499671732
demonstrate,0.022222411499671732
donor,0.022092183614526206
lesions,0.022092183614526206
60,0.022092183614526206
groups,0.022092183614526206
samples,0.022092183614526206
chimerism,0.022092183614526206
total,0.022092183614526206
anterior,0.022092183614526206
complications,0.022092183614526206
outcome,0.022092183614526206
intravenous,0.022092183614526206
refractory,0.022092183614526206
uc,0.02147504564313861
inferior,0.02147504564313861
infiltrate,0.02147504564313861
fecal,0.02147504564313861
morbidity,0.02147504564313861
lineage,0.02147504564313861
status,0.019785068999802397
intensive,0.019785068999802397
sle,0.019785068999802397
laboratory,0.019785068999802397
corticosteroids,0.019785068999802397
different,0.019785068999802397
identical,0.019785068999802397
experimental,0.019785068999802397
pembrolizumab,0.019785068999802397
transfusion,0.019785068999802397
48,0.019785068999802397
covid,0.019785068999802397
isatuximab,0.019785068999802397
historical,0.019785068999802397
major,0.019785068999802397
pharmacodynamics,0.018828881861379584
prognostic,0.018828881861379584
identify,0.018828881861379584
maintenance,0.018828881861379584
40mg,0.018828881861379584
sf,0.018828881861379584
organs,0.018828881861379584
effectiveness,0.018828881861379584
adherence,0.018828881861379584
extension,0.018828881861379584
rejection,0.018828881861379584
leakage,0.018828881861379584
haplo,0.017673746891620965
optimal,0.017673746891620965
signs,0.017673746891620965
end,0.017673746891620965
red,0.017673746891620965
characteristics,0.017673746891620965
following,0.017673746891620965
probability,0.017673746891620965
assessed,0.017673746891620965
plasma,0.017673746891620965
daily,0.017673746891620965
high,0.017673746891620965
treatments,0.017673746891620965
19,0.017673746891620965
macular,0.017673746891620965
adverse,0.017673746891620965
edema,0.017673746891620965
collection,0.017673746891620965
involvement,0.017673746891620965
steroid,0.017673746891620965
evolution,0.017673746891620965
event,0.017673746891620965
global,0.0166668086247538
sarcoma,0.0166668086247538
future,0.0166668086247538
responders,0.0166668086247538
kidney,0.0166668086247538
bone,0.0166668086247538
pcr,0.0166668086247538
impact,0.0166668086247538
hydrogen,0.0166668086247538
hours,0.0166668086247538
toxicities,0.0166668086247538
talimogene,0.0166668086247538
80mg,0.0166668086247538
immunological,0.0166668086247538
allograft,0.0166668086247538
renal,0.0166668086247538
needs,0.0166668086247538
lymphocyte,0.0166668086247538
genetic,0.0166668086247538
twice,0.0166668086247538
relative,0.0166668086247538
endemic,0.0166668086247538
ion,0.0166668086247538
pan,0.0166668086247538
intermediate,0.0166668086247538
initial,0.0166668086247538
clinically,0.0166668086247538
laherparepvec,0.0166668086247538
conventional,0.0166668086247538
ml,0.0166668086247538
expression,0.0166668086247538
finding,0.016591029399451125
tcr,0.016591029399451125
cyp2c19,0.016591029399451125
explain,0.016591029399451125
interactions,0.016591029399451125
signatures,0.016591029399451125
covariate,0.016591029399451125
funding,0.016591029399451125
2g,0.016591029399451125
cyp2d6,0.016591029399451125
modulation,0.016591029399451125
mrd1,0.016591029399451125
mucosal,0.016591029399451125
comparatively,0.016591029399451125
specificity,0.016591029399451125
cognitive,0.016591029399451125
viral,0.014838801749851797
inflammatory,0.014838801749851797
overload,0.014838801749851797
antibiotics,0.014838801749851797
receiving,0.014838801749851797
iron,0.014838801749851797
comparison,0.014838801749851797
occurrence,0.014838801749851797
organ,0.014838801749851797
classic,0.014838801749851797
skin,0.014838801749851797
sparing,0.014838801749851797
need,0.014838801749851797
appendix,0.014838801749851797
serum,0.014838801749851797
late,0.014838801749851797
criteria,0.014838801749851797
residual,0.014838801749851797
requiring,0.014838801749851797
biopsies,0.014838801749851797
measure,0.014838801749851797
understand,0.01431669709542574
56,0.01431669709542574
immunophenotyping,0.01431669709542574
monocytes,0.01431669709542574
dysfunction,0.01431669709542574
ig,0.01431669709542574
censoring,0.01431669709542574
c2d1,0.01431669709542574
nelarabine,0.01431669709542574
correlate,0.01431669709542574
microbiota,0.01431669709542574
phenotype,0.01431669709542574
household,0.01431669709542574
transcriptomic,0.01431669709542574
30,0.013255310168715723
duration,0.013255310168715723
met,0.013255310168715723
weeks,0.013255310168715723
infection,0.013255310168715723
current,0.013255310168715723
step,0.013255310168715723
interval,0.013255310168715723
additional,0.013255310168715723
increase,0.013255310168715723
prca,0.013255310168715723
posterior,0.013255310168715723
events,0.013255310168715723
vitreous,0.013255310168715723
associated,0.013255310168715723
vessel,0.013255310168715723
unit,0.013255310168715723
retinal,0.013255310168715723
peripheral,0.013255310168715723
infections,0.013255310168715723
phase,0.013255310168715723
validate,0.012552587907586388
42,0.012552587907586388
induction,0.012552587907586388
inactive,0.012552587907586388
pharmacokinetics,0.012552587907586388
2005,0.012552587907586388
provisional,0.012552587907586388
prospectively,0.012552587907586388
profiles,0.012552587907586388
base,0.012552587907586388
c4,0.012552587907586388
complement,0.012552587907586388
rank,0.012552587907586388
quantification,0.012552587907586388
platform,0.012552587907586388
inferiority,0.012552587907586388
vs,0.012552587907586388
subcutaneously,0.012552587907586388
diagnostic,0.012552587907586388
biology,0.012552587907586388
adults,0.012552587907586388
molecular,0.012552587907586388
dependency,0.012552587907586388
diffuse,0.012552587907586388
load,0.012552587907586388
examinations,0.012552587907586388
exploratory,0.012552587907586388
orally,0.012552587907586388
old,0.012552587907586388
tolerability,0.012552587907586388
comorbidity,0.012552587907586388
alloimmunization,0.012552587907586388
cycle,0.011111205749835866
determine,0.011111205749835866
dna,0.011111205749835866
du,0.011111205749835866
better,0.011111205749835866
allo,0.011111205749835866
setting,0.011111205749835866
lung,0.011111205749835866
malignant,0.011111205749835866
immunogenicity,0.011111205749835866
hypothesis,0.011111205749835866
mesylate,0.011111205749835866
lupus,0.011111205749835866
magnetic,0.011111205749835866
35,0.011111205749835866
underlying,0.011111205749835866
cd,0.011111205749835866
candidate,0.011111205749835866
scores,0.011111205749835866
comparing,0.011111205749835866
niu,0.011111205749835866
correlated,0.011111205749835866
oral,0.011111205749835866
complementary,0.011111205749835866
cure,0.011111205749835866
resonance,0.011111205749835866
grfs,0.011111205749835866
chemotherapy,0.011111205749835866
sample,0.011111205749835866
center,0.011111205749835866
role,0.011111205749835866
gene,0.011111205749835866
collected,0.009892534499901198
threatening,0.009892534499901198
therapies,0.009892534499901198
allow,0.009892534499901198
imaging,0.009892534499901198
confirmed,0.009892534499901198
perform,0.009892534499901198
points,0.009892534499901198
infusions,0.009892534499901198
paris,0.009892534499901198
vascular,0.009892534499901198
line,0.009892534499901198
liver,0.009892534499901198
marrow,0.009892534499901198
responses,0.009892534499901198
manifestations,0.009892534499901198
reduction,0.009892534499901198
release,0.009892534499901198
regulatory,0.009892534499901198
received,0.009892534499901198
ratio,0.009892534499901198
haze,0.009892534499901198
radiation,0.009892534499901198
cyclophosphamide,0.009892534499901198
cutaneous,0.009892534499901198
minimal,0.009892534499901198
mean,0.009892534499901198
parameters,0.009892534499901198
evaluation,0.009892534499901198
kaposi,0.009892534499901198
counts,0.009892534499901198
costs,0.009892534499901198
camostat,0.009892534499901198
previous,0.009892534499901198
endpoints,0.009892534499901198
appropriate,0.009892534499901198
presence,0.009892534499901198
prednisone,0.009892534499901198
neutrophil,0.009892534499901198
inhibitor,0.009892534499901198
included,0.009892534499901198
ii,0.008836873445810483
steroids,0.008836873445810483
40,0.008836873445810483
order,0.008836873445810483
severity,0.008836873445810483
second,0.008836873445810483
injection,0.008836873445810483
sensitivity,0.008836873445810483
cryoglobulinemia,0.008836873445810483
previously,0.008836873445810483
assessment,0.008836873445810483
death,0.008836873445810483
health,0.008836873445810483
unrelated,0.008836873445810483
resolution,0.008836873445810483
corticosteroid,0.008836873445810483
capmatinib,0.008836873445810483
eye,0.008836873445810483
specific,0.008836873445810483
followed,0.008836873445810483
toxicity,0.008836873445810483
considered,0.008836873445810483
stool,0.008295514699725563
4th,0.008295514699725563
ikzf1,0.008295514699725563
imagine,0.008295514699725563
patterns,0.008295514699725563
162mg,0.008295514699725563
omeprazole,0.008295514699725563
pdl1,0.008295514699725563
ophthalmologic,0.008295514699725563
optimize,0.008295514699725563
organized,0.008295514699725563
pectoral,0.008295514699725563
placebos,0.008295514699725563
picomolar,0.008295514699725563
phases,0.008295514699725563
contacted,0.008295514699725563
notch1,0.008295514699725563
nutritional,0.008295514699725563
pellets,0.008295514699725563
certain,0.008295514699725563
ago,0.008295514699725563
alloreactivity,0.008295514699725563
fraall2000,0.008295514699725563
immunomonitoring,0.008295514699725563
strategies,0.008295514699725563
supervisor,0.008295514699725563
supportive,0.008295514699725563
surrogacy,0.008295514699725563
acquisition,0.008295514699725563
hydroxyomeprazole,0.008295514699725563
nevous,0.008295514699725563
exhaustion,0.008295514699725563
exploring,0.008295514699725563
potency,0.008295514699725563
mrna,0.008295514699725563
multicentricity,0.008295514699725563
sections,0.008295514699725563
node,0.008295514699725563
signals,0.008295514699725563
signature,0.008295514699725563
excellence,0.008295514699725563
influence,0.008295514699725563
fbxw7,0.008295514699725563
amplified,0.008295514699725563
professor,0.008295514699725563
production,0.008295514699725563
cellular,0.008295514699725563
modifies,0.008295514699725563
montparnasse,0.008295514699725563
prevalance,0.008295514699725563
belgium,0.008295514699725563
rouge,0.008295514699725563
eradicated,0.008295514699725563
interrogating,0.008295514699725563
banked,0.008295514699725563
iterative,0.008295514699725563
kind,0.008295514699725563
kinetic,0.008295514699725563
efferocytosis,0.008295514699725563
elaborate,0.008295514699725563
archival,0.008295514699725563
anomalies,0.008295514699725563
intensified,0.008295514699725563
intensification,0.008295514699725563
anas,0.008295514699725563
improves,0.008295514699725563
indices,0.008295514699725563
experiments,0.008295514699725563
lpf,0.008295514699725563
lymph,0.008295514699725563
assays,0.008295514699725563
mediator,0.008295514699725563
reproducibility,0.008295514699725563
repercussions,0.008295514699725563
biomarker,0.008295514699725563
biocollection,0.008295514699725563
rating,0.008295514699725563
ras,0.008295514699725563
boost,0.008295514699725563
broad,0.008295514699725563
biochemical,0.008295514699725563
bilirubine,0.008295514699725563
bio,0.008295514699725563
bioactivity,0.008295514699725563
mast,0.008295514699725563
rehospitalizations,0.008295514699725563
reinforced,0.008295514699725563
listed,0.008295514699725563
microbiological,0.008295514699725563
quantified,0.008295514699725563
pten,0.008295514699725563
proton,0.008295514699725563
views,0.008295514699725563
16s,0.008295514699725563
cyp3a4,0.008295514699725563
mirna,0.008295514699725563
mll,0.008295514699725563
pump,0.008295514699725563
variability,0.008295514699725563
want,0.008295514699725563
100mg,0.008295514699725563
variations,0.008295514699725563
haematopoietic,0.008295514699725563
75015,0.008295514699725563
hermine,0.008295514699725563
globule,0.008295514699725563
transport,0.008295514699725563
2d6,0.008295514699725563
2x106,0.00715834854771287
tumour,0.00715834854771287
graall2003,0.00715834854771287
gonadic,0.00715834854771287
glucose,0.00715834854771287
hematologic,0.00715834854771287
hemagglutinins,0.00715834854771287
80c,0.00715834854771287
75475,0.00715834854771287
vellefaux,0.00715834854771287
48h,0.00715834854771287
vod,0.00715834854771287
vh,0.00715834854771287
24h,0.00715834854771287
cy,0.00715834854771287
pyelonephritis,0.00715834854771287
protocols,0.00715834854771287
prognosis,0.00715834854771287
dendritic,0.00715834854771287
reached,0.00715834854771287
caecum,0.00715834854771287
bvas,0.00715834854771287
brands,0.00715834854771287
boulevard,0.00715834854771287
randomly,0.00715834854771287
mcr,0.00715834854771287
dry,0.00715834854771287
respective,0.00715834854771287
disability,0.00715834854771287
ll03,0.00715834854771287
enterobacteriaceae,0.00715834854771287
rennes,0.00715834854771287
mra,0.00715834854771287
cytometry,0.00715834854771287
cardio,0.00715834854771287
laboratoire,0.00715834854771287
kaposis,0.00715834854771287
ex,0.00715834854771287
evaluating,0.00715834854771287
avenue,0.00715834854771287
inspired,0.00715834854771287
sepsis,0.00715834854771287
screened,0.00715834854771287
schemes,0.00715834854771287
routine,0.00715834854771287
precision,0.00715834854771287
practitioner,0.00715834854771287
negativation,0.00715834854771287
necker,0.00715834854771287
native,0.00715834854771287
muscular,0.00715834854771287
sodium,0.00715834854771287
slicc,0.00715834854771287
situation,0.00715834854771287
siti,0.00715834854771287
sf36,0.00715834854771287
erythematosus,0.00715834854771287
stages,0.00715834854771287
feasibility,0.00715834854771287
ancillary,0.00715834854771287
analyse,0.00715834854771287
alterations,0.00715834854771287
alteration,0.00715834854771287
specimens,0.00715834854771287
phenotypes,0.00715834854771287
continued,0.00715834854771287
concurrent,0.00715834854771287
normalization,0.00715834854771287
pharmacokinetic,0.00715834854771287
gastrointestinal,0.00715834854771287
gastrectomy,0.00715834854771287
immunomodulation,0.00715834854771287
aimed,0.00715834854771287
supervision,0.00715834854771287
tract,0.00715834854771287
tnfa,0.00715834854771287
immunologic,0.00715834854771287
immuno,0.00715834854771287
ac,0.00715834854771287
switzerland,0.00715834854771287
pancreatitis,0.00715834854771287
org,0.00715834854771287
opioids,0.00715834854771287
olivier,0.00715834854771287
collections,0.00715834854771287
claude,0.00715834854771287
chu,0.00715834854771287
365,0.00715834854771287
150mg,0.00715834854771287
undergoing,0.006276293953793194
graaph,0.006276293953793194
hospitalisation,0.006276293953793194
actg,0.006276293953793194
acr,0.006276293953793194
pediatric,0.006276293953793194
optimized,0.006276293953793194
conclusion,0.006276293953793194
comparative,0.006276293953793194
colonized,0.006276293953793194
controls,0.006276293953793194
colon,0.006276293953793194
college,0.006276293953793194
clinical,0.006276293953793194
circulating,0.006276293953793194
tarte,0.006276293953793194
immunotherapy,0.006276293953793194
gammaglobulin,0.006276293953793194
functional,0.006276293953793194
frozen,0.006276293953793194
fresh,0.006276293953793194
immunomodulatory,0.006276293953793194
allocated,0.006276293953793194
conduct,0.006276293953793194
condition,0.006276293953793194
check,0.006276293953793194
charlson,0.006276293953793194
ch50,0.006276293953793194
cervical,0.006276293953793194
persistent,0.006276293953793194
affected,0.006276293953793194
surgical,0.006276293953793194
success,0.006276293953793194
subpopulation,0.006276293953793194
subgroups,0.006276293953793194
sub,0.006276293953793194
stored,0.006276293953793194
storage,0.006276293953793194
stenosis,0.006276293953793194
state,0.006276293953793194
necrosis,0.006276293953793194
myeloablative,0.006276293953793194
mscs,0.006276293953793194
phenotyping,0.006276293953793194
chelation,0.006276293953793194
fertility,0.006276293953793194
improve,0.006276293953793194
analyze,0.006276293953793194
sri,0.006276293953793194
spontaneous,0.006276293953793194
inform,0.006276293953793194
infiltration,0.006276293953793194
social,0.006276293953793194
monotherapy,0.006276293953793194
mononuclear,0.006276293953793194
cd20,0.006276293953793194
cd19,0.006276293953793194
priapism,0.006276293953793194
sight,0.006276293953793194
eradication,0.006276293953793194
intensity,0.006276293953793194
anxiety,0.006276293953793194
antidepressant,0.006276293953793194
serological,0.006276293953793194
sequential,0.006276293953793194
scd,0.006276293953793194
rifaximin,0.006276293953793194
rheumatology,0.006276293953793194
rheumatoid,0.006276293953793194
radiotherapy,0.006276293953793194
curve,0.006276293953793194
ctc,0.006276293953793194
metabolic,0.006276293953793194
ptcy,0.006276293953793194
proteinuria,0.006276293953793194
estimation,0.006276293953793194
autoantibodies,0.006276293953793194
resistant,0.006276293953793194
diagnosed,0.006276293953793194
lines,0.006276293953793194
length,0.006276293953793194
lead,0.006276293953793194
equivalent,0.006276293953793194
eq5d,0.006276293953793194
bilag,0.006276293953793194
lymphoma,0.006276293953793194
recurrence,0.006276293953793194
recipients,0.006276293953793194
recently,0.006276293953793194
reactants,0.006276293953793194
c3,0.006276293953793194
breast,0.006276293953793194
logmar,0.006276293953793194
determination,0.006276293953793194
detection,0.006276293953793194
derived,0.006276293953793194
deciliter,0.006276293953793194
59,0.006276293953793194
transmission,0.006276293953793194
ciprofloxacin,0.006276293953793194
participate,0.006276293953793194
vasopressors,0.006276293953793194
250,0.006276293953793194
2003,0.005555602874917933
virological,0.005555602874917933
voc,0.005555602874917933
usually,0.005555602874917933
49,0.005555602874917933
adequate,0.005555602874917933
ventilation,0.005555602874917933
like,0.005555602874917933
directly,0.005555602874917933
hopital,0.005555602874917933
hgf,0.005555602874917933
hemolytic,0.005555602874917933
damage,0.005555602874917933
mechanical,0.005555602874917933
gr,0.005555602874917933
depression,0.005555602874917933
detected,0.005555602874917933
bmt,0.005555602874917933
lymphocytes,0.005555602874917933
measurement,0.005555602874917933
reduced,0.005555602874917933
real,0.005555602874917933
receive,0.005555602874917933
ref,0.005555602874917933
biopsy,0.005555602874917933
replacement,0.005555602874917933
respiratory,0.005555602874917933
association,0.005555602874917933
programme,0.005555602874917933
procedures,0.005555602874917933
examination,0.005555602874917933
biomarkers,0.005555602874917933
relapses,0.005555602874917933
activation,0.005555602874917933
grafalon,0.005555602874917933
cerebral,0.005555602874917933
consumption,0.005555602874917933
cohorts,0.005555602874917933
american,0.005555602874917933
moderate,0.005555602874917933
cov,0.005555602874917933
creatinine,0.005555602874917933
allows,0.005555602874917933
extra,0.005555602874917933
eyes,0.005555602874917933
infliximab,0.005555602874917933
infarct,0.005555602874917933
fludarabine,0.005555602874917933
formula,0.005555602874917933
chosen,0.005555602874917933
induced,0.005555602874917933
fish,0.005555602874917933
analyzed,0.005555602874917933
aml,0.005555602874917933
cytokines,0.005555602874917933
area,0.005555602874917933
fact,0.005555602874917933
initiation,0.005555602874917933
institut,0.005555602874917933
erythrocyte,0.005555602874917933
interim,0.005555602874917933
sledai,0.005555602874917933
silent,0.005555602874917933
causes,0.005555602874917933
saint,0.005555602874917933
selena,0.005555602874917933
screening,0.005555602874917933
bleeding,0.005555602874917933
blinded,0.005555602874917933
mismatch,0.005555602874917933
mmol,0.005555602874917933
clearance,0.005555602874917933
negative,0.005555602874917933
stroke,0.005555602874917933
surface,0.005555602874917933
functions,0.005555602874917933
general,0.005555602874917933
overlap,0.005555602874917933
achieved,0.005555602874917933
05,0.005555602874917933
transplanted,0.005555602874917933
www,0.005555602874917933
29,0.005555602874917933
aa,0.005555602874917933
treosulfan,0.005555602874917933
acs,0.005555602874917933
abo,0.005555602874917933
person,0.005555602874917933
stay,0.005555602874917933
mud,0.005555602874917933
phenotypic,0.005555602874917933
aged,0.005555602874917933
context,0.005555602874917933
immunosuppressive,0.005555602874917933
considering,0.004946267249950599
iii,0.004946267249950599
absence,0.004946267249950599
hospital,0.004946267249950599
hospitalizations,0.004946267249950599
committee,0.004946267249950599
bd,0.004946267249950599
proportion,0.004946267249950599
review,0.004946267249950599
thrombosis,0.004946267249950599
withdrawal,0.004946267249950599
transfusions,0.004946267249950599
heart,0.004946267249950599
visit,0.004946267249950599
uninjected,0.004946267249950599
frequency,0.004946267249950599
obtain,0.004946267249950599
notably,0.004946267249950599
pr,0.004946267249950599
course,0.004946267249950599
spartalizumab,0.004946267249950599
monitoring,0.004946267249950599
start,0.004946267249950599
flow,0.004946267249950599
starting,0.004946267249950599
size,0.004946267249950599
long,0.004946267249950599
louis,0.004946267249950599
delayed,0.004946267249950599
body,0.004946267249950599
good,0.004946267249950599
low,0.004946267249950599
belimumab,0.004946267249950599
matched,0.004946267249950599
mds,0.004946267249950599
calculated,0.004946267249950599
reduce,0.004946267249950599
leukocyte,0.004946267249950599
follows,0.004946267249950599
exposure,0.004946267249950599
anemia,0.004946267249950599
18,0.004946267249950599
type,0.004946267249950599
ileal,0.004946267249950599
able,0.004946267249950599
33,0.004946267249950599
percentage,0.004946267249950599
performance,0.004946267249950599
https,0.004946267249950599
support,0.004946267249950599
neurological,0.004946267249950599
population,0.004946267249950599
point,0.004946267249950599
therapeutic,0.004946267249950599
syndromes,0.004946267249950599
plan,0.004946267249950599
platelet,0.004946267249950599
exposed,0.004946267249950599
cycles,0.004946267249950599
injected,0.004946267249950599
approach,0.004946267249950599
scale,0.004946267249950599
right,0.004946267249950599
antibodies,0.004946267249950599
antigen,0.004946267249950599
symptoms,0.004946267249950599
single,0.004946267249950599
factor,0.004946267249950599
source,0.004946267249950599
surgery,0.004946267249950599
validated,0.004418436722905241
20,0.004418436722905241
measures,0.004418436722905241
evidence,0.004418436722905241
kilograms,0.004418436722905241
doses,0.004418436722905241
reported,0.004418436722905241
recommendations,0.004418436722905241
rates,0.004418436722905241
management,0.004418436722905241
value,0.004418436722905241
50,0.004418436722905241
tnf,0.004418436722905241
70,0.004418436722905241
adapted,0.004418436722905241
vasculitis,0.004418436722905241
data,0.004418436722905241
sars,0.004418436722905241
medical,0.004418436722905241
independent,0.004418436722905241
amplification,0.004418436722905241
increased,0.004418436722905241
model,0.004418436722905241
procedure,0.004418436722905241
milligrams,0.004418436722905241
cardiac,0.004418436722905241
pre,0.004418436722905241
syndrome,0.004418436722905241
france,0.004418436722905241
period,0.004418436722905241
observed,0.004418436722905241
poor,0.004418436722905241
test,0.004418436722905241
greater,0.004418436722905241
human,0.004418436722905241
